Effects of gemcitabine on renal function in patients with non-small cell lung cancer

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 199-202

  Gietema, J A ^a   Groen, H J M ^a   Meijer, S ^a   Smit, E F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Gemcitabine; Non small cell lung cancer; Renal function

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; GEMCITABINE; IODOHIPPURATE SODIUM I 131; IOTALAMIC ACID I 125; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; ERYTHROCYTES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RENAL PLASMA FLOW, EFFECTIVE;

EID: 0031914720     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00354-7     Document Type: Article

References (12)

1. Braakhuis BJM, Van Dongen GAMS, Vermorken JB. Preclinical in vivo activity of 2,2-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991, 51, 211-214.
2. Hertel LW, Boder GB, Kroin JS. Evaluation of the antirumour activity of gemcitabine, (difluoro-2-deoxycytidine). Cancer Res 1990, 50, 4417-4422.
3. O Rourke TJ, Brown TD, Havlin K. Phase I clinical trials of gemcitabine as an intravenous bolus on 5 consecutive days. Eur J Cancer 1994, 30, 417-418.
4. Poplin E, Corbett T, Flaherty L. Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs 1992, 10, 165-170.
5. Abruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 12, 491-498.
6. Kaye SB. Genicitabine: Current status of phase I and II trials. J Clin Oncol 1994, 12, 1527-1531.
7. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994, 12, 1535-1540.
8. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994, 12, 1821-1826.
9. Gatzemeier U, Sheperd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996, 32A, 243-248.
10. Donker AJM, van der Hem GK, Sluicer WJ, Beekhuis A. A radioisotope method for simultaneous détermination of the glomerular nitration rate and the effective renal plasma flow. Neth J Med 1977, 20, 97-103.
11. Evrin PE, Peterson PA, Wide L, Berggard I. Radioimmunoassay of 2-microglobulin in human biological fluids. Scand J Clin Invest 1971, 28, 439-443.
12. Watanabe N, Kamei S, Ohkubo A, et al. Urinary protein as measured with a pyrogallol red-rnolybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986, 32, 1551-1554.